Finance
Novo Nordisk Shares Under Pressure as REDEFINE 4 Clinical Trial Results Fall Short
Novo Nordisk has released top-line results from its REDEFINE 4 Phase 3 obesity trial, which failed to meet high market expectations. The data marks a rare setback for the pharmaceutical leader in the highly competitive weight-loss drug sector.
February 23, 2026691 views
Score0
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Finance
Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown
1d ago
Finance
Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings
1d ago
Finance
Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch
1d ago
Finance
Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule
1d ago
Comments (0)
Sign in to leave a comment.
No comments yet. Be the first to share your thoughts!